# RETRACTION: Combination of Aloin and Metformin Enhances the Antitumor Effect by Inhibiting the Growth and Invasion and Inducing Apoptosis and Autophagy in Hepatocellular Carcinoma Through PI3K/AKT/mTOR Pathway

PMC · DOI: 10.1002/cam4.70055 · Cancer Medicine · 2024-08-14

## TL;DR

This retracted study claimed that combining aloin and metformin could fight liver cancer by affecting specific cell pathways, but errors and image duplication invalidated the findings.

## Contribution

The paper was retracted due to significant data errors and image duplication, invalidating its novel claim about the antitumor effects of aloin and metformin in liver cancer.

## Key findings

- The study was retracted due to significant data collection and analysis errors.
- Image duplication was found in figures, compromising the paper's conclusions.
- The authors could not support the original claims about the PI3K/AKT/mTOR pathway effects.

## Abstract

RETRACTION: R. Sun, R. Zhai, C. Ma, and W. Miao, “Combination of Aloin and Metformin Enhances the Antitumor Effect by Inhibiting the Growth and Invasion and Inducing Apoptosis and Autophagy in Hepatocellular Carcinoma Through PI3K/AKT/mTOR Pathway,” Cancer Medicine 9, no. 3 (2020): 1141–1151, https://doi.org/10.1002/cam4.2723.

The above article, published online on 12 December 2019 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors; the journal Editor‐in‐Chief, Stephen Tait; and John Wiley and Sons Ltd. The authors asked to retract the article as they found significant errors in the data collection and analysis, therefore the conclusions of the paper are not supported. Subsequently, an investigation into concerns raised by a third party revealed inappropriate duplication of images (Figure 1C, 2B and 4C, D) between this and other articles that were previously published or published shortly after in a different scientific context. Thus, the editors consider the conclusions of this manuscript substantially compromised. Although the authors initially asked for the retraction, when asked to approve the retraction wording, they remained unresponsive.

## Linked entities

- **Chemicals:** Aloin (PubChem CID 9866696), Metformin (PubChem CID 4091)
- **Diseases:** Hepatocellular Carcinoma (MONDO:0007256)

## Full-text entities

- **Genes:** MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}
- **Diseases:** Cancer (MESH:D009369), Hepatocellular Carcinoma (MESH:D006528)
- **Chemicals:** Aloin (MESH:C006457), Metformin (MESH:D008687)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11322991/full.md

---
Source: https://tomesphere.com/paper/PMC11322991